Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection?

Reid, Richard; Greenberg, Mitchell; Lörincz, Attila T.; Jenson, A. Bennett; Laverty, Colin R.; Husain, Mujtaba; Daoud, Yahya; Zado, Barina; White, Thomas; Cantor, David; Goldrath, Milton H.

doi:10.1016/0002-9378(91)91425-v

Cited by 102 publications

(42 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical value of HPV detection for screening for SIL has been shown in several studies (Reid et al, 1991;Cuzick et al, 1995;Schneider et al, 1996). However, the majority of SIL identi®ed in screening programs regress spontaneously and identi®cation of progression markers is mandatory in order to avoid overtreatment.…”

Section: Introductionmentioning

confidence: 99%

Identification of novel molecular markers which correlate with HPV-induced tumor progression

et al. 1998

View full text Add to dashboard Cite

High risk HPVs (human papillomaviruses) are causally involved in the development of cervical cancer. However, other factors, such as somatic genetic alterations also play a decisive role in malignant conversion of cervical keratinocytes. Mutations and chromosomal aberrations are known to in¯uence the pattern of gene expression. Therefore we used the recently developed RT ± PCR based method of di erential display of mRNAs to detect di erences in gene expression which correlate with tumorigenicity. Non-tumorigenic HPV16-immortalized human foreskin keratinocytes (HPK IA) were compared with their tumorigenic counterparts and 49 di erent genes were identi®ed which were either up-or downregulated. The identi®ed genes encode proteins of the cytoskeleton and the extracellular matrix, the nuclear splicing apparatus, transcription regulators and membrane-associated proteins. The expression pattern of all genes was also examined by RNA ± RNA in situ hybridization in biopsies of normal cervical epithelium, precancerous lesions and cancers. Two genes, C4.8 and C21.7, are of particular interest because their expression is upregulated in a subset of high grade precancerous lesions and in over 58% of cancers. These two genes may therefore be considered as putative progression markers. C4.8 is a new member of the transmembrane 4 (TM-4) protein family which includes tumor-associated antigens such as CD63 and TAPA-1, whereas C21.7 shows no signi®cant homologies to any known genes or proteins.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of novel molecular markers which correlate with HPV-induced tumor progression

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Sensitivities for cytology of only 40-80% for highgrade cervical intraepithelial neoplasia (CIN II/III) have been reported (Reid et al, 1991;Cox et al, 1995;Cuzick et al, 1995). Furthermore, cytologic screening is poor at detecting glandular lesions or adenocarcinoma, which account for a growing number of cervical cancers (Kjaer and Brinton, 1993;Vizcaino, et al, 1998).…”

mentioning

confidence: 99%

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

Cuzick¹,

Sasieni²,

Davies

et al. 2000

Br J Cancer

137

View full text Add to dashboard Cite

A systematic review of the available evidence on the role of HPV testing in cervical screening has been published by the Health Technology Assessment Committee of the UK Department of Health. The review summarized relevant data on testing methods, natural history, and prevalence of the virus in different disease groups. Cost-effectiveness modelling was undertaken. Ten major conclusions were reached and are reported here. The key conclusions were that HPV testing was more sensitive than cytology, but that there were concerns about specificity, especially in young women. The increased sensitivity led to a recommendation that HPV testing be introduced on a pilot basis for women with borderline and mild smears. HPV testing has great potential as a primary screening test, but large trials are needed to properly evaluate this application and to determine if its introduction can reduce invasive cancer rates. There is an urgent need to undertake a large trial of HPV testing in conjunction with other new technologies (liquid-based cytology and computer-assisted cytology reading) to determine the best way to integrate them into ongoing screening programmes. A range of issues including the age to start and stop screening, the appropriate screening interval, the role of self-sampling for HPV testing and the choice of primary test (HPV and/or cytology) require further evaluation. © 2000 Cancer Research Campaign

show abstract

“…However, there is considerable interlaboratory variability in detection of SILs and up to 20% of SILs can go undetected by routine screening procedures [9][10][11][12] . Additionally 5-10% of women with the diagnosis of ASCUS harbor SILs and more than one-third of screening populations who harbor high-grade intraepithelial lesions are identified from ASCUS results 6 .…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Typing in HIV‐Positive Women

Hameed

Fernandes

Skurnick³

et al. 2001

Infectious Diseases in Obstetrics and Gynecology

View full text Add to dashboard Cite

Objective: Human papillomavirus (HPV) is the major cause of cervical carcinoma and cervical intraepithelial neoplasia worldwide. Certain HPV types have a strong association with and probably a causative role in the pathogenesis of premalignant cervical lesions. Epidemiologic studies in women infected by the human immunodeficiency virus (HIV) have shown an increased incidence of squamous intraepithelial lesions (SILs), which were predominantly high-grade. Six to 30 per cent of women diagnosed with atypical squamous cells of undetermined significance (ASCUS) on a Papanicolaou (Pap) smear harbor SIL in normal screening populations. This study was undertaken to determine the presence of low-and high-risk HPV types in women infected by HIV and to correlate the results to those of the Pap smear. Study design: HPV DNA typing (low-and high-risk) by Digeneä (Digene Corporation, Gathesburg, MD) hybrid capture methodology was performed on cervical swabs from 209 HIV-positive women. The results of HPV typing were correlated with those of the Pap smear in a retrospective analysis. Results: One hundred and one women (48%) tested positive for HPV subtypes by DNA typing by the hybrid capture method. Of these, 64 patients (63%) had Pap smears which were read as being normal, having benign cellular changes, or having ASCUS (favor reactive process). Of these, 19 patients tested positive for both high-risk and low-risk subtypes, 32 patients tested positive only for high-risk subtypes, and 13 patients tested positive only for low-risk subtypes. Conclusion: HPV subtyping identifies a significant group of HIV-positive women who are at risk for developing cervical intraepithelial neoplasia, although they may not show significant abnormalities on their Pap smears.

show abstract

Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection?

Cited by 102 publications

References 8 publications

Identification of novel molecular markers which correlate with HPV-induced tumor progression

Identification of novel molecular markers which correlate with HPV-induced tumor progression

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions

Human Papillomavirus Typing in HIV‐Positive Women

Contact Info

Product

Resources

About